See more : Pressure Technologies plc (PRES.L) Income Statement Analysis – Financial Results
Complete financial analysis of Vertex Pharmaceuticals Incorporated (VRTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vertex Pharmaceuticals Incorporated, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Bhagwati Autocast Limited (BGWTATO.BO) Income Statement Analysis – Financial Results
- Urja Global Limited (URJA.NS) Income Statement Analysis – Financial Results
- Harvest Health & Recreation Inc. (HRVSF) Income Statement Analysis – Financial Results
- PT Natura City Developments Tbk (CITY.JK) Income Statement Analysis – Financial Results
- Everbrite Technology Co., Ltd. (4523.TWO) Income Statement Analysis – Financial Results
Vertex Pharmaceuticals Incorporated (VRTX)
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.87B | 8.93B | 7.57B | 6.21B | 4.16B | 3.05B | 2.49B | 1.70B | 1.03B | 580.42M | 1.21B | 1.53B | 1.41B | 143.37M | 102.05M | 175.50M | 199.01M | 216.36M | 160.89M | 102.72M | 69.14M | 161.09M | 167.49M | 78.13M | 61.60M | 44.40M | 43.80M | 13.30M | 22.10M | 19.60M | 27.90M | 3.80M | 3.20M | 2.30M |
| Cost of Revenue | 1.26B | 1.08B | 904.20M | 736.30M | 547.76M | 409.54M | 275.12M | 210.46M | 125.54M | 60.99M | 130.28M | 279.89M | 80.51M | 12.73M | 14.20M | 15.69M | 13.90M | 12.17M | 10.10M | 5.65M | 3.13M | 28.28M | 39.63M | 4.08M | -3.40M | -4.50M | -3.60M | -3.20M | -3.70M | -3.50M | -3.90M | -2.80M | -1.80M | 0.00 |
| Gross Profit | 8.61B | 7.85B | 6.67B | 5.47B | 3.62B | 2.64B | 2.21B | 1.49B | 906.79M | 519.43M | 1.08B | 1.25B | 1.33B | 130.64M | 87.85M | 159.82M | 185.11M | 204.19M | 150.79M | 97.07M | 66.02M | 132.80M | 127.86M | 74.05M | 65.00M | 48.90M | 47.40M | 16.50M | 25.80M | 23.10M | 31.80M | 6.60M | 5.00M | 2.30M |
| Gross Profit Ratio | 87.21% | 87.90% | 88.06% | 88.14% | 86.84% | 86.56% | 88.95% | 87.64% | 87.84% | 89.49% | 89.25% | 81.67% | 94.29% | 91.12% | 86.08% | 91.06% | 93.01% | 94.38% | 93.72% | 94.50% | 95.48% | 82.44% | 76.34% | 94.78% | 105.52% | 110.14% | 108.22% | 124.06% | 116.74% | 117.86% | 113.98% | 173.68% | 156.25% | 100.00% |
| Research & Development | 3.16B | 2.54B | 3.05B | 1.83B | 1.75B | 1.42B | 1.32B | 1.05B | 996.17M | 855.51M | 918.78M | 806.19M | 707.71M | 637.42M | 550.69M | 516.29M | 513.05M | 371.71M | 248.54M | 192.16M | 199.64M | 203.02M | 148.67M | 84.92M | 72.20M | 58.70M | 51.60M | 35.20M | 41.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 401.43M | 352.58M | 289.21M | 342.74M | 378.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 31.40M | 24.50M | 16.20M | 19.60M | 58.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.14B | 944.70M | 840.10M | 770.46M | 658.50M | 557.62M | 496.08M | 432.83M | 377.08M | 305.41M | 362.34M | 436.80M | 400.72M | 187.80M | 129.30M | 101.91M | 84.73M | 57.86M | 43.99M | 42.14M | 39.08M | 49.39M | 47.34M | 27.81M | 26.10M | 18.10M | 11.40M | 7.90M | 7.10M | 40.30M | 26.70M | 13.80M | 8.80M | 6.40M |
| Other Expenses | 475.50M | -164.80M | 4.90M | 296.42M | 192.18M | -790.00K | -81.38M | 4.13M | -6.71M | 30.40M | -72.67M | 44.99M | 124.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.30M | 4.50M | 3.60M | 3.20M | 3.70M | 3.50M | 3.90M | 2.80M | 1.80M | 0.00 |
| Operating Expenses | 4.78B | 3.49B | 3.89B | 2.60B | 2.41B | 1.97B | 1.82B | 1.48B | 1.37B | 1.16B | 1.28B | 1.24B | 1.11B | 825.22M | 679.98M | 618.20M | 597.78M | 429.57M | 292.53M | 234.30M | 238.72M | 252.41M | 196.01M | 112.73M | 104.60M | 81.30M | 66.60M | 46.30M | 52.30M | 43.80M | 30.60M | 16.60M | 10.60M | 6.40M |
| Cost & Expenses | 6.04B | 4.57B | 4.80B | 3.34B | 2.96B | 2.38B | 2.10B | 1.69B | 1.50B | 1.22B | 1.41B | 1.52B | 1.19B | 837.95M | 694.18M | 633.89M | 611.69M | 441.74M | 302.63M | 239.95M | 241.84M | 280.69M | 235.64M | 116.81M | 101.20M | 76.80M | 63.00M | 43.10M | 48.60M | 40.30M | 26.70M | 13.80M | 8.80M | 6.40M |
| Interest Income | 614.70M | 144.60M | 4.90M | 22.24M | 63.68M | 0.00 | 11.75M | 0.00 | 0.00 | 0.00 | 0.00 | 1.94M | 1.88M | 1.96M | 5.01M | 16.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 44.10M | 54.80M | 61.50M | 58.15M | 58.50M | 34.12M | 57.55M | 81.43M | 84.21M | 72.86M | 22.73M | 14.71M | 36.57M | 19.28M | 13.19M | 13.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 181.30M | 148.30M | 125.60M | 109.52M | 106.94M | 72.42M | 61.40M | 61.40M | 62.34M | 63.26M | 48.37M | 38.19M | 35.04M | 30.46M | 30.11M | 32.20M | 27.46M | 25.87M | 27.29M | 29.64M | 23.44M | 25.43M | 17.96M | 9.10M | 6.30M | 4.50M | 3.60M | 3.20M | 3.70M | 3.50M | 3.90M | 2.80M | 1.80M | 0.00 |
| EBITDA | 4.61B | 4.44B | 2.92B | 3.28B | 1.56B | 706.78M | 103.26M | 75.46M | -411.25M | -598.76M | -554.75M | 42.46M | 133.94M | -704.89M | -598.88M | -426.19M | -385.21M | -199.52M | -114.45M | -107.59M | -264.53M | -123.05M | -97.14M | -24.65M | -44.30M | -43.20M | -15.60M | -36.30M | -22.80M | -17.20M | 5.10M | -7.20M | -3.80M | -4.10M |
| EBITDA Ratio | 46.66% | 48.65% | 36.82% | 51.37% | 35.02% | 21.76% | 12.51% | 0.90% | -45.83% | -105.28% | 41.63% | 0.27% | 15.72% | -461.86% | -531.80% | -260.35% | -189.99% | -93.32% | -56.52% | -101.15% | -96.10% | -58.43% | -14.39% | -18.77% | -52.92% | -62.84% | -35.62% | -127.07% | -128.05% | -106.12% | 13.26% | -242.11% | -143.75% | -178.26% |
| Operating Income | 4.31B | 4.31B | 2.78B | 2.86B | 1.20B | 635.15M | 123.24M | 9.94M | -468.66M | -692.41M | -903.45M | 2.33M | 113.82M | -696.08M | -613.41M | -462.71M | -419.79M | -229.04M | -149.87M | -154.81M | -264.53M | -119.60M | -91.80M | -38.68M | -39.60M | -32.40M | -19.20M | -29.80M | -26.50M | -20.70M | 1.20M | -10.00M | -5.60M | -4.10M |
| Operating Income Ratio | 43.65% | 48.23% | 36.73% | 46.03% | 28.77% | 20.84% | 4.95% | 0.58% | -45.40% | -119.30% | -74.54% | 0.15% | 8.07% | -485.51% | -601.10% | -263.65% | -210.94% | -105.86% | -93.15% | -150.71% | -382.59% | -74.25% | -54.81% | -49.51% | -64.29% | -72.97% | -43.84% | -224.06% | -119.91% | -105.61% | 4.30% | -263.16% | -175.00% | -178.26% |
| Total Other Income/Expenses | 72.30M | -75.00M | -51.70M | 62.80M | 197.42M | -34.91M | -138.93M | -77.30M | -90.92M | -42.46M | -366.11M | -59.11M | -53.38M | -58.55M | -28.17M | 2.86M | 28.51M | 21.10M | -53.55M | -11.44M | 67.76M | 28.30M | -2.79M | -16.16M | 10.30M | 0.00 | 0.00 | 0.00 | 5.50M | 3.60M | 900.00K | 2.00M | 800.00K | 4.10M |
| Income Before Tax | 4.38B | 4.23B | 2.73B | 3.12B | 1.39B | 600.24M | -15.69M | -67.37M | -559.58M | -734.88M | -976.12M | -12.38M | 60.45M | -754.63M | -642.18M | -464.18M | -426.91M | -206.89M | -173.39M | -158.51M | -347.35M | -119.66M | -117.89M | -53.61M | -40.30M | 0.00 | 0.00 | -39.50M | -21.00M | -17.10M | 2.10M | -8.00M | -4.80M | 0.00 |
| Income Before Tax Ratio | 44.38% | 47.39% | 36.05% | 50.22% | 33.51% | 19.70% | -0.63% | -3.96% | -54.21% | -126.61% | -80.54% | -0.81% | 4.28% | -526.35% | -629.28% | -264.48% | -214.52% | -95.63% | -107.77% | -154.31% | -502.38% | -74.28% | -70.39% | -68.62% | -65.42% | 0.00% | 0.00% | -296.99% | -95.02% | -87.24% | 7.53% | -210.53% | -150.00% | 0.00% |
| Income Tax Expense | 760.20M | 910.40M | 388.30M | 405.15M | 218.11M | -1.49B | -107.32M | 16.67M | 30.38M | 6.96M | -288.57M | 38.75M | 19.27M | 19.28M | 19.34M | -30.73M | -21.39M | -18.50M | 61.68M | 29.01M | 24.06M | -10.98M | -1.92M | 976.00K | 1.40M | 700.00K | 600.00K | 10.20M | -5.00M | -3.10M | 100.00K | -1.50M | -500.00K | 4.30M |
| Net Income | 3.62B | 3.32B | 2.34B | 2.71B | 1.18B | 2.10B | 263.48M | -112.05M | -558.12M | -738.56M | -445.03M | -107.03M | 29.57M | -754.63M | -641.58M | -459.85M | -391.28M | -206.89M | -203.42M | -166.25M | -196.77M | -108.62M | -66.23M | -39.66M | -41.00M | -33.10M | -19.80M | -40.00M | -21.50M | -17.60M | 2.00M | -8.50M | -5.10M | -4.30M |
| Net Income Ratio | 36.68% | 37.20% | 30.92% | 43.70% | 28.27% | 68.80% | 10.59% | -6.58% | -54.06% | -127.25% | -36.72% | -7.01% | 2.10% | -526.35% | -628.70% | -262.02% | -196.61% | -95.63% | -126.43% | -161.85% | -284.59% | -67.43% | -39.54% | -50.76% | -66.56% | -74.55% | -45.21% | -300.75% | -97.29% | -89.80% | 7.17% | -223.68% | -159.38% | -186.96% |
| EPS | 14.05 | 12.97 | 9.09 | 10.44 | 4.58 | 8.25 | 1.06 | -0.46 | -2.32 | -3.14 | -1.98 | -0.50 | 0.14 | -3.77 | -3.70 | -3.27 | -3.03 | -1.83 | -2.28 | -2.12 | -2.56 | -1.43 | -0.89 | -0.59 | -0.80 | -0.65 | -0.41 | -1.07 | -0.63 | -0.56 | 0.08 | -0.35 | -0.35 | -0.33 |
| EPS Diluted | 13.89 | 12.82 | 9.01 | 10.29 | 4.51 | 8.09 | 1.04 | -0.46 | -2.31 | -3.14 | -1.98 | -0.50 | 0.14 | -3.77 | -3.70 | -3.27 | -3.03 | -1.83 | -2.28 | -2.12 | -2.56 | -1.43 | -0.89 | -0.59 | -0.80 | -0.65 | -0.41 | -1.07 | -0.63 | -0.56 | 0.08 | -0.35 | -0.35 | -0.33 |
| Weighted Avg Shares Out | 257.70M | 256.10M | 257.70M | 259.84M | 256.73M | 254.29M | 248.86M | 243.59M | 240.84M | 234.92M | 224.83M | 211.95M | 204.89M | 200.40M | 173.26M | 140.56M | 128.99M | 113.22M | 89.24M | 78.57M | 77.00M | 75.75M | 74.46M | 67.68M | 51.04M | 50.60M | 48.53M | 37.38M | 34.13M | 31.43M | 25.00M | 24.29M | 14.62M | 13.03M |
| Weighted Avg Shares Out (Dil) | 260.50M | 259.10M | 259.90M | 263.40M | 260.67M | 259.19M | 253.23M | 244.69M | 241.31M | 235.31M | 224.91M | 211.95M | 208.81M | 200.40M | 173.26M | 140.56M | 128.99M | 113.22M | 89.24M | 78.57M | 77.00M | 75.75M | 74.46M | 67.68M | 51.04M | 50.60M | 48.53M | 37.38M | 34.13M | 31.43M | 25.00M | 24.29M | 14.62M | 13.03M |
Hunting For Magnificent Growth Next Year? Check Out These 7 Stocks.
None of our picks is Nvidia or Apple or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.
Vertex to Announce Third Quarter 2024 Financial Results on November 4th
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2024 financial results on Monday, November 4, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the...
2 Biotech Stocks to Buy Hand Over Fist in October
These longtime leading biotech stocks still have plenty of upside ahead.
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $448.16, signifying a -1.57% move from its prior day's close.
3 Top Stocks That Could Still Rocket Higher in 2024
Upcoming Food and Drug Administration decisions could push these stocks through the roof.
2 Superior Growth Stocks That Are Screaming Buys Right Now
These companies have plenty of growth runway left.
Vertex Pharmaceuticals (VRTX) Surpasses Market Returns: Some Facts Worth Knowing
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $465.08, denoting a +0.48% change from the preceding trading day.
Wall Street Analysts See Vertex (VRTX) as a Buy: Should You Invest?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis Conference
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the first accepted medical presentations of the Phase 3 data on the investigational once daily vanzacaftor/tezacaftor/deutivacaftor (“vanza triple”) — the potential next-in-class triple combination medicine — will take place at the North...
Source: https://incomestatements.info
Category: Stock Reports